Wuhan Jianmin Pharmaceutical Group
Wuhan Jianmin Pharmaceutical engages in the research and development, production, and sale of pharmaceuticals primarily in China.
Launch date
Employees
Market cap
CAD1.2b
Enterprise valuation
CAD1.1b (Public information from Sep 2024)
Share price
CNY41.65 600976.SS
Wuhan Hubei (HQ)
Financials
Estimates*
| CNY | 2019 | 2020 | 2021 | 2022 | 2023 | 2025 |
|---|---|---|---|---|---|---|
| Revenues | 2.2b | 2.5b | 3.3b | 3.6b | 4.2b | 40.4b |
| % growth | - | 10 % | 33 % | 11 % | 16 % | - |
| EBITDA | 128m | 182m | 399m | 519m | 626m | - |
| % EBITDA margin | 6 % | 7 % | 12 % | 14 % | 15 % | - |
| Profit | 91.5m | 148m | 325m | 408m | 521m | - |
| % profit margin | 4 % | 6 % | 10 % | 11 % | 12 % | - |
| R&D budget | 41.0m | 37.4m | 52.6m | 73.2m | 74.0m | - |
| R&D % of revenue | 2 % | 2 % | 2 % | 2 % | 2 % | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
| Total Funding | - | ||
Related Content
Recent News about Wuhan Jianmin Pharmaceutical Group
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
